Ignite Creation Date:
2025-12-25 @ 2:30 AM
Ignite Modification Date:
2026-01-08 @ 4:57 AM
Study NCT ID:
NCT00491634
Status:
COMPLETED
Last Update Posted:
2015-12-02
First Post:
2007-06-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Treosulfan-based Conditioning for Transplantation in AML/MDS
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D015470', 'term': 'Leukemia, Myeloid, Acute'}, {'id': 'D009190', 'term': 'Myelodysplastic Syndromes'}], 'ancestors': [{'id': 'D007951', 'term': 'Leukemia, Myeloid'}, {'id': 'D007938', 'term': 'Leukemia'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D001855', 'term': 'Bone Marrow Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C018404', 'term': 'treosulfan'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 24}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2007-06'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2015-11', 'completionDateStruct': {'date': '2014-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2015-11-30', 'studyFirstSubmitDate': '2007-06-25', 'studyFirstSubmitQcDate': '2007-06-25', 'lastUpdatePostDateStruct': {'date': '2015-12-02', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2007-06-26', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2014-06', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'disease-free survival', 'timeFrame': '2 years after transplantation'}], 'secondaryOutcomes': [{'measure': 'treatment-related mortality, GVHD, relapse, overall survival', 'timeFrame': '2 year after transplantation'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['acute myeloid leukemia', 'myelodysplastic syndrome', 'allogeneic stem cell transplantation', 'reduced-intensity conditioning', 'treosulfan'], 'conditions': ['Acute Myeloid Leukemia', 'Myelodysplastic Syndrome']}, 'referencesModule': {'references': [{'pmid': '16415898', 'type': 'BACKGROUND', 'citation': 'Kroger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F, Wolschke C, Renges H, Dahlke J, Atanackovic D, Nagler A, Zander A. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant. 2006 Feb;37(4):339-44. doi: 10.1038/sj.bmt.1705259.'}]}, 'descriptionModule': {'briefSummary': 'The study hypotheses is that the introduction of dose escalated treosulfan, in substitution to busulfan, will reduce toxicity after allogeneic transplantation while improving myeloablation and and disease control in patients with AML and MDS not eligible for standard transplantation.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '68 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Age less than physiologic 68 years.\n2. Patients with AML and MDS not eligible for standard TBI- or Busulfan-based myeloablative conditioning due to age, concurrent medical condition, or extensive prior therapy (e.g. age \\> 55 years for HLA-matched sibling transplants or \\> 50 for matched unrelated donor transplants, prior / concomitant pulmonary, liver, or other organ complications).\n3. This study will only include patients with chemo-refractory disease or previously untreated active disease.\n\n A. acute myeloid leukemias (AML) according to WHO classification (\\> 20% myeloblasts in peripheral blood or bone marrow at diagnosis) in induction failure, PR, untreated or chemo-refractory relapse. Patients must have \\> 10% marrow blasts at the time of transplantation.\n\n B. myelodysplastic syndromes (MDS) according to WHO classification (\\< 20% myeloblasts in peripheral blood and bone marrow at diagnosis), indicated for allogeneic transplantation:\n\n \\- refractory anaemia with excess blasts (RAEB-1 and RAEB-2) with no prior therapy\n4. Patients must have an HLA matched related or unrelated donor willing to donate either peripheral blood stem cells or bone marrow. Matching is based on high-resolution class I (HLA-A, -B, -C) and class II (HLA-DRB1, -DQB1) typing. The goal is to transplant \\> 3 x 106 CD34+ cells per kg body weight of the recipient -\n\nExclusion Criteria:\n\n1. Bilirubin \\> 3.0 mg/dl, transaminases \\> 3 times upper normal limit\n2. Creatinine \\> 2.0 mg/dl\n3. ECOG-Performance status \\> 2\n4. Uncontrolled infection\n5. Pregnancy or lactation\n6. Abnormal lung diffusion capacity (DLCO \\< 40% predicted)\n7. Severe cardiovascular disease\n8. CNS disease involvement\n9. Pleural effusion or ascites \\> 1 liter\n10. Known hypersensitivity to fludarabine or treosulfan\n11. Psychiatric conditions/disease that impair the ability to give informed consent or to adequately co-operate -'}, 'identificationModule': {'nctId': 'NCT00491634', 'briefTitle': 'Treosulfan-based Conditioning for Transplantation in AML/MDS', 'organization': {'class': 'OTHER_GOV', 'fullName': 'Sheba Medical Center'}, 'officialTitle': 'Phase II Trial of Fludarabine Combined With Intravenous Treosulfan and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Chemo-refractory or Previously Untreated Acute Myeloid Leukemia and Myelodysplastic Syndrome.', 'orgStudyIdInfo': {'id': 'SHEBA-07-3116-AN-CTIL'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': '1', 'description': 'treosulfan', 'interventionNames': ['Drug: treosulfan']}], 'interventions': [{'name': 'treosulfan', 'type': 'DRUG', 'description': '12 g/m2 x 3 days', 'armGroupLabels': ['1']}, {'name': 'Treosulfan', 'type': 'DRUG', 'description': '12 g/m2 x 3', 'armGroupLabels': ['1']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Tel Litwinsky', 'country': 'Israel', 'facility': 'Chaim Sheba Medical Center', 'geoPoint': {'lat': 32.05096, 'lon': 34.84588}}], 'overallOfficials': [{'name': 'Arnon Nagler, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Chaim Sheba Medical Center'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Dr. Avichai Shimoni MD', 'class': 'OTHER_GOV'}, 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Dr. Avichai Shimoni', 'investigatorFullName': 'Dr. Avichai Shimoni MD', 'investigatorAffiliation': 'Sheba Medical Center'}}}}